Swiss stocks - Factors to watch on October 19
Swiss stocks - Factors to watch on October 19 ZURICH/GDANSK, Oct 19 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday:
Norway, Switzerland, Iceland and Liechtenstein have signed a free-trade agreement with Vietnam, the governments of Norway and Vietnam announced on Sunday.
Rising public debt levels in Europe and beyond pose a risk to economic stability and could trigger a euro crisis, Swiss Finance Minister Karin Keller-Sutter said on Friday.
COMPANY STATEMENTS
ALCON AG ALCC.S
FDA approves Alcon's Brytly Redness Reliever eye drops for up to 12 hours of whiter, brighter-looking eyes.
NOVARTIS NOVN.S
Swiss drugmaker Novartis has terminated a mid-stage study testing its drug Fabhalta in patients with a serious kidney condition, citing "strategic considerations", according to a federal clinical trials registry.
ECONOMY
SNB sight deposits due at 0800 GMT.
(Reporting by Zurich newsroom and Gdansk newsroom)
((+41 58 306 7336; zurich.newsroom@thomsonreuters.com))
For Top News in a multimedia Web format on Eikon visit: https://bit.ly/2NDFd6g
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German .SDE
All SMI constituent stocks 0#.SSMI
DJ STOXX index .STOXX
Top 10 STOXX sectors .PGL.STOXXS
Top 10 EUROSTOXX sectors .PGL.STOXXES
Swiss mid-cap index .SSMI
Swiss all-share index .SSHI
Swiss market digest .AD.S
Sector overview CH/SECTOR1
All Swiss news CH
Swiss research news CH-RCH
All equity news E
SPEED GUIDES: EQUITY, EQUITY/NEWS1, EUR/EQUITY, SWITZERLAND, REUTERS
Recent news on Alcon AG
See all newsBrief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
Brief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
Swiss stocks - Factors to watch on October 19
Brief: FDA Approves Alcon’S BRYTL Eye Drops
Advisory: Alert incorrectly tagged to Omega Interactive Technologies withdrawn